Want to see MRKR full AI Analyst Report?
Top Page
Marker Therapeutics
(NASDAQ:MRKR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:Reiterated
Date:07/08/26
The score is primarily held down by weak financial performance (declining revenue, negative gross profit, sizable losses, and ongoing cash burn), partially offset by a relatively supportive technical backdrop with the price trading above key moving averages. Valuation remains constrained because the negative P/E reflects unprofitable operations and there is no dividend yield support.
Positive Factors
Multi-tumor antigen T-cell platform
Marker’s core platform concentrates on multi-tumor antigen-specific adoptive T‑cells, a durable scientific differentiator. Targeting multiple antigens can reduce tumor-escape risk and broaden addressable indications across hematologic and solid tumors, supporting long-term pipeline optionality if clinical progress continues.
Negative Factors
Sustained negative cash flow
Persistent negative operating and free cash flow shows the business is not self-funding and will rely on external capital. Recurrent cash burn constrains investment in trials and manufacturing, increases dilution risk from financings, and creates ongoing execution pressure across the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-tumor antigen T-cell platform
Marker’s core platform concentrates on multi-tumor antigen-specific adoptive T‑cells, a durable scientific differentiator. Targeting multiple antigens can reduce tumor-escape risk and broaden addressable indications across hematologic and solid tumors, supporting long-term pipeline optionality if clinical progress continues.
Read all positive factors
Marker Therapeutics (MRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.84M
Dividend YieldN/A
Average Volume (3M)66.98K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth-43.86%
EPS Growth49.21%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,673,126
10 Day Avg. Volume79,434
30 Day Avg. Volume66,977
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.36
Price to Sales (P/S)0.00
P/FCF Ratio-1.90
Enterprise Value/Market Cap-0.01
Enterprise Value/Revenue-0.16
Enterprise Value/Gross Profit0.05
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$9.00Price Target Upside442.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$2.73M
Marker Therapeutics Business Overview & Revenue Model
Company Description
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both ...
How the Company Makes Money
null...
Marker Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.09M | 0.00 | 6.59M | 3.31M | 3.51M | 1.24M |
| Gross Profit | -7.27M | 0.00 | -6.88M | -7.11M | -8.45M | -1.92M |
| EBITDA | -10.91M | -12.44M | -10.68M | -11.25M | -16.99M | -38.72M |
| Net Income | -10.90M | -12.16M | -10.73M | -8.24M | -29.93M | -41.88M |
Balance Sheet | ||||||
| Total Assets | 17.43M | 19.07M | 22.02M | 17.13M | 34.42M | 68.14M |
| Cash, Cash Equivalents and Short-Term Investments | 14.92M | 16.07M | 19.19M | 15.11M | 11.78M | 42.35M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | 11.87M |
| Total Liabilities | 3.64M | 2.27M | 3.46M | 3.07M | 14.82M | 24.15M |
| Stockholders Equity | 13.80M | 16.80M | 18.56M | 14.05M | 19.60M | 43.99M |
Cash Flow | ||||||
| Free Cash Flow | -7.92M | -12.01M | -10.91M | -16.44M | -26.97M | -30.41M |
| Operating Cash Flow | -7.92M | -12.01M | -10.91M | -16.44M | -26.97M | -27.28M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 18.66M | -4.95M | -3.13M |
| Financing Cash Flow | 9.86M | 9.86M | 14.99M | 1.11M | 202.13K | 52.56M |
Marker Therapeutics Technical Analysis
Positive
1.66
Price Trends
1.44
Positive
1.44
Positive
1.38
Positive
Market Momentum
0.04
Negative
60.88
Neutral
76.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Positive. The current price of 1.66 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.44, and above the 200-day MA of 1.38, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.88 is Neutral, neither overbought nor oversold. The STOCH value of 76.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRKR.
Marker Therapeutics Risk Analysis
Marker Therapeutics disclosed 55 risk factors in its most recent earnings report. Marker Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Marker Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $12.65M | -0.09 | ― | ― | ― | 80.65% | |
48 Neutral | $26.84M | -2.36 | -73.29% | ― | -43.86% | 49.21% | |
46 Neutral | $75.51M | -2.62 | -53.86% | ― | -20.00% | 75.26% | |
45 Neutral | $52.52M | -12.62 | -92.03% | ― | -100.00% | -170.04% | |
45 Neutral | $6.25M | -0.72 | -71.27% | ― | -50.79% | -180.59% | |
43 Neutral | $18.46M | -1.67 | -112.05% | ― | ― | 94.17% |
* Healthcare Sector Average
MRKR
Marker Therapeutics
1.58
-0.13
-7.60%
IBIO
Ibio
1.51
0.70
85.50%
MBRX
Moleculin Biotech
2.44
-11.31
-82.26%
ABVC
ABVC BioPharma
1.45
-2.52
-63.48%
ADXN
Addex Therapeutics
5.88
-2.96
-33.47%
ALLR
Allarity Therapeutics
1.20
0.19
18.81%
Marker Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Marker Therapeutics Shareholders Approve Governance and Capital Changes
Positive
May 4, 2026
At its May 1, 2026 annual meeting, Marker Therapeutics’ shareholders re-elected all five director nominees and approved, on an advisory basis, executive compensation, while also ratifying CBIZ CPAs P.C. as the independent auditor for the 202...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.